Insys Therapeutics (INSY) Misses Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts INSY Hot Sheet
Join SI Premium – FREE
Insys Therapeutics (NASDAQ: INSY) reported Q2 Adj. EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $38 million versus the consensus estimate of $25.91 million.
For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Methanex (MEOH) Tops Q3 EPS by 87c
- Pro-Dex (PDEX) Tops Q1 EPS by 26c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
